{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:28:55Z","timestamp":1779110935685,"version":"3.51.4"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by inflammatory lesions, often leading to scarring. Managing HS can be difficult, requiring biological therapy, specifically adalimumab. Methods: A retrospective study was conducted on patients diagnosed with HS and treated with the TNF-\u03b1 inhibitor adalimumab. Data from 21 patients were included in this study. International Hidradenitis Suppurativa Severity Score System (IHS4); Dermatology Life Quality Index (DLQI); pain intensity according to the Visual Analogue Scale (VAS); and number of nodules, abscesses, and fistulas were assessed. Results: Notably, 47.62% of patients achieved Hidradenitis Suppurativa Clinical Response. The mean number of inflamed nodules decreased from 5.62 \u00b1 4.12 to 3 \u00b1 3.46, abscesses decreased from 1.76 \u00b1 2.63 to 0.81 \u00b1 1.4, and fistulas decreased from 2.62 \u00b1 1.86 to 2 \u00b1 1.9 (p &lt; 0.05). The IHS4 score decreased from 19 \u00b1 10.78 to 12.62 \u00b1 11.13 (p = 0.001), DLQI from 15.76 \u00b1 7.73 to 7.43 \u00b1 7.76 (p &lt; 0.001), and VAS from 6.69 \u00b1 1.56 to 3.64 \u00b1 2.65 (p &lt; 0.001). There was a significant difference in the baseline IHS4 scores between patients who had prior surgery with a mean score of 23.86 \u00b1 9.4 versus non-surgical patients with a mean IHS4 score of 9.29 \u00b1 5.53 (p = 0.001). Conclusions: About half of HS patients responded positively to adalimumab treatment; the use of the drug reduces inflammatory lesions, and pain, and improves quality of life.<\/jats:p>","DOI":"10.3390\/clinpract14050135","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:58:46Z","timestamp":1724759926000},"page":"1696-1706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center"],"prefix":"10.3390","volume":"14","author":[{"given":"Aust\u0117ja","family":"\u0160akaityt\u0117","sequence":"first","affiliation":[{"name":"Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"\u010cesnavi\u010di\u016bt\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8852-1846","authenticated-orcid":false,"given":"Tadas","family":"Raudonis","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Phan, K., Charlton, O., and Smith, S.D. (2020). Global prevalence of hidradenitis suppurativa and geographical variation\u2014Systematic review and meta-analysis. Biomed. Dermatol., 4.","DOI":"10.1186\/s41702-019-0052-0"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Seyed Jafari, S.M., Hunger, R.E., and Schlapbach, C. (2020). Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00068"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_10","first-page":"e178","article-title":"Current and future treatment of hidradenitis suppurativa","volume":"183","author":"Prens","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: A series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: A prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: A practical framework for treatment optimization\u2013systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/jdv.17598","article-title":"Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: The 1-year SOLACE study","volume":"35","author":"Gulliver","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12737","DOI":"10.1111\/dth.12737","article-title":"Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience","volume":"31","author":"Bettoli","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study","volume":"17","author":"Martora","year":"2024","journal-title":"CCID"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","first-page":"e15691","article-title":"Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis Suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"1547","article-title":"Hidradenitis suppurativa: A treatment challenge","volume":"72","author":"Shah","year":"2005","journal-title":"Am. Fam. Physician"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bjd.17919","article-title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: Integrated results from the phase III randomized placebo-controlled PIONEER trials","volume":"181","author":"Jemec","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/1346-8138.16297","article-title":"Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan","volume":"49","author":"Hayashi","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e3640285","DOI":"10.1155\/2023\/3640285","article-title":"Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic","volume":"2023","author":"Smetanova","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"adv00172","DOI":"10.2340\/00015555-3520","article-title":"Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience","volume":"100","author":"Chiricozzi","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","article-title":"The validation of visual analogue scales as ratio scale measures for chronic and experimental pain","volume":"17","author":"Price","year":"1983","journal-title":"Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","article-title":"Hidradenitis suppurativa: Viewpoint on clinical phenotyping, pathogenesis and novel treatments","volume":"21","author":"Laman","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0625.2012.01443.x","article-title":"Is mechanical stress an important pathogenic factor in hidradenitis suppurativa?","volume":"21","author":"Prens","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa: A systematic review and meta-analysis of observational studies","volume":"173","author":"Tzellos","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjd.19713","article-title":"Trends in body mass index before and after diagnosis of hidradenitis suppurativa","volume":"185","author":"Wright","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/ijd.16565","article-title":"Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa","volume":"62","author":"Nosrati","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","article-title":"Hidradenitis suppurativa: A retrospective study of 846 Dutch patients to identify factors associated with disease severity","volume":"71","author":"Schrader","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1203475419874412","article-title":"Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review","volume":"24","author":"Sivanand","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1800","article-title":"The Influence of Body Weight on the Prevalence and Severity of Hidradenitis Suppurativa","volume":"94","author":"Kromann","year":"2014","journal-title":"Acta Derm.-Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2015.08.061","article-title":"Hidradenitis suppurativa: Demystifying a chronic and debilitating disease","volume":"73","author":"Alavi","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/SAP.0000000000000584","article-title":"Outcomes After Combined Radical Resection and Targeted Biologic Therapy for the Management of Recalcitrant Hidradenitis Suppurativa","volume":"77","author":"DeFazio","year":"2016","journal-title":"Ann. Plast. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1097\/PRS.0000000000002671","article-title":"What Heals Hidradenitis Suppurativa: Surgery, Immunosuppression, or Both?","volume":"138","author":"Falola","year":"2016","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/ijd.13798","article-title":"Longitudinal observational study of hidradenitis suppurativa: Impact of surgical intervention with adjunctive biologic therapy","volume":"57","author":"Shanmugam","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","article-title":"Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting","volume":"89","author":"Aarts","year":"2023","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/5\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:28Z","timestamp":1760111008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/5\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["clinpract14050135"],"URL":"https:\/\/doi.org\/10.3390\/clinpract14050135","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}